読み込み中
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
前日終値
$12.50
+$0.40 · +3.31%
日中の時刻はETです。市場データは遅延する場合があります。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日中レンジ
現在 $12.50
52週レンジ
現在 $12.50
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
55
適正価値
センチメント
57
まちまち
リスク
53
やや高いリスク
モメンタム
49
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV). The company also holds a strategic partnership and licensing agreement with Abbott Laboratories. This collaboration involves the joint identification, development, and market introduction of specific HCV NS3 and NS3/4A protease inhibitor compounds, including known agents like paritaprevir and glecaprevir, which are utilized in the management of chronic hepatitis C virus. Founded in 1995, Enanta Pharmaceuticals, Inc. operates from its principal office located in Watertown, Massachusetts.
日中レンジ
現在 $12.50
52週レンジ
現在 $12.50
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 6532.4万 USD | 6763.5万 USD | 7920.4万 USD | 8616万 USD | 9707.4万 USD |
| 売上原価 | 458.6万 USD | — | — | — | — |
| 粗利益 | 6073.8万 USD | 6763.5万 USD | 7920.4万 USD | 8616万 USD | 9707.4万 USD |
| 研究開発 | 1.07億 USD | 1.31億 USD | 1.64億 USD | 1.65億 USD | 1.74億 USD |
| 販売・一般管理 | 4393.3万 USD | 5785万 USD | 5288.7万 USD | 4548.2万 USD | 3253.6万 USD |
| 営業費用 | 1.46億 USD | 1.89億 USD | 2.16億 USD | 2.1億 USD | 2.07億 USD |
| 受取利息 | 948.1万 USD | 1477万 USD | 1136万 USD | 157.3万 USD | 202.1万 USD |
| 支払利息 | 768.1万 USD | 1094万 USD | 514.8万 USD | — | — |
| 減価償却費と償却費 | 508.9万 USD | 233.6万 USD | 237.1万 USD | 297.3万 USD | 333.4万 USD |
| 営業利益 | −8534.9万 USD | −1.22億 USD | −1.37億 USD | −1.24億 USD | −1.1億 USD |
| 純利益 | −8188.9万 USD | −1.16億 USD | −1.34億 USD | −1.22億 USD | −7899.6万 USD |
会社概要が更新されました 2026年10月10日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
